Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873952 | 1.00 | EPHX1 (0.37) | EPHX1SHBGTP53MEN1ALDH1A1 | |
| SCHEMBL2021417 | 1.00 | EPHX1 (0.37) | EPHX1SHBGTP53MEN1ALDH1A1 | |
| SCHEMBL8296257 | 0.97 | EPHX1 (0.33) | EPHX1SHBGTP53MEN1ALDH1A1 | |
| SCHEMBL5720721 | 0.95 | EPHX1 (0.37) | EPHX1SHBGTP53MEN1ALDH1A1 | |
| SCHEMBL5462680 | 0.95 | EPHX1 (0.32) | EPHX1SHBGTP53CYP1A2 | |
| SCHEMBL9697174 | 0.92 | — | — | |
| SCHEMBL8781239 | 0.81 | — | — | |
| SCHEMBL14931538 | 0.76 | METAP1 (0.41) | EPHX1SHBGTP53CYP1A2 | |
| SCHEMBL4449485 | 0.76 | METAP1 (0.41) | EPHX1SHBGTP53CYP1A2 | |
| SCHEMBL21753853 | 0.76 | METAP1 (0.41) | EPHX1SHBGTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569928-A4 | THERAPEUTIC COMPOUNDS AND METHODS | GOVERNMENT OF THE STATE OF SAR (MY) | 2008-12-10 | — | — | EP | claimed |
| JP-2006508098-A | — | — | 2006-03-09 | — | — | JP | claimed |
| EP-1569928-A1 | THERAPEUTIC COMPOUNDS AND METHODS | The Government of the State of Sarawak, Malaysia (MY) | 2005-09-07 | — | — | EP | claimed |
| WO-2004041812-A1 | THERAPEUTIC COMPOUNDS AND METHODS | THE GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2004-05-21 | — | — | WO | claimed |
| US-20030181514-A1 | Therapeutic compounds and methods | GOVERNMENT OF THE STATE OF SARAWAK, MALAYSIA (MY) | 2003-09-25 | — | — | US | claimed |
| WO-2023163082-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE BATTERY COMPRISING SAID NONAQUEOUS ELECTROLYTE SOLUTION, AND COMPOUND | ＭＵアイオニックソリューションズ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| US-11635685-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20220026803-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20210149300-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| CN-1254463-C | Flexible method for the combined production of formic acid and carboxylic acids having at least two carbon atoms and/or derivatives thereof | BASF AG (DE) | 2006-05-03 | — | — | CN | disclosed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181514-A1 | Therapeutic compounds and methods | DHFR, CPT1A, NDUFAB1 | EPHX1 565/4885SHBG 917/4885TP53 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.